Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Positron Emission Tomography (PET) Cardiac Applications are considered in medical policy 00103.

Note: Positron Emission Tomography (PET) Oncology Applications are considered in medical policy 00105.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) in the diagnosis of chronic osteomyelitis to be eligible for coverage.**

Based on review of available data, the Company may consider positron emission tomography (PET) using FDG in the assessment of selected patients with epileptic seizures who are candidates for surgery to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for the use of positron emission tomography (PET) in the assessment of selected patients with epileptic seizures will be considered when the following criteria are met:

• Complex partial epileptic seizures that have failed to respond to medical therapy; and
• Resection of a suspected epileptogenic focus located in a region of the brain accessible to surgery has been recommended; and
• Conventional noninvasive techniques for seizure localization must have been tried and provided data that suggested a seizure focus, but were not sufficiently conclusive to permit surgery; and
• The purpose of the positron emission tomography (PET) examination should be to avoid subjecting the patient to extended preoperative electroencephalographic (EEG) recording with implanted electrodes or to help localize and minimize the number of sites for implanted electrodes to reduce the morbidity of that procedure.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
When Services Are Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of FDG-PET for all other miscellaneous indications, including but not limited to the following, to be investigational:*  

Central Nervous System (CNS) diseases

- Autoimmune disorders with CNS manifestations, including:
  - Behçet’s syndrome
  - Lupus erythematosus
- Cerebrovascular diseases, including:
  - Arterial occlusive disease (arteriosclerosis, atherosclerosis)
  - Carotid artery disease
  - Cerebral aneurysm
  - Cerebrovascular malformations (AVM and Moya disease)
  - Hemorrhage
  - Infarct
  - Ischemia
- Degenerative motor neuron diseases, including:
  - Amyotrophic lateral sclerosis
  - Friedreich’s ataxia
  - Olivopontocerebellar atrophy
  - Parkinson’s disease
  - Progressive supranuclear palsy
  - Shy-Drager syndrome
  - Spinocerebellar degeneration
  - Steele-Richardson-Olszewski disease
  - Tourette’s syndrome
- Dementias, including:
  - Alzheimer’s disease
  - Multi-infarct dementia
  - Pick disease
  - Frontotemporal dementia
  - Dementia with Lewy-Bodies
  - Presenile dementia
- Demyelinating diseases, such as multiple sclerosis
- Developmental, congenital, or inherited disorders, including:
  - Adrenoleukodystrophy
  - Down’s syndrome
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

- Huntington’s chorea
- Kinky-hair disease (Menkes’ syndrome)
- Sturge-Weber syndrome (encephalofacial angiomatosis) and the phakomatoses

- Miscellaneous
  - Chronic fatigue syndrome
  - Sick building syndrome
  - Post-traumatic stress disorder

- Nutritional or metabolic diseases and disorders, including:
  - Acanthocytosis
  - Hepatic encephalopathy
  - Hepatolenticular degeneration
  - Metachromatic leukodystrophy
  - Mitochondrial disease
  - Subacute necrotizing encephalomyelopathy

- Psychiatric diseases and disorders, including:
  - Affective disorders
  - Depression
  - Obsessive-compulsive disorder
  - Psychomotor disorders
  - Schizophrenia

- Pyogenic infections, including:
  - Aspergillosis
  - Encephalitis

- Substance abuse, including the CNS effects of alcohol, cocaine and heroin

- Trauma, including brain injury and carbon monoxide poisoning

- Viral infections, including:
  - Acquired immune deficiency syndrome (AIDS)
  - AIDS dementia complex
  - Creutzfeldt-Jakob syndrome
  - Progressive multifocal leukoencephalopathy
  - Progressive rubella encephalopathy
  - Subacute sclerosing panencephalitis

- Mycobacterium infection
- Migraine
- Anorexia nervosa
- Assessment of cerebral blood flow in newborns
  - Vegetative versus locked-in syndrome

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Pulmonary diseases
- Adult respiratory distress syndrome
- Diffuse panbronchiolitis
- Emphysema
- Obstructive lung disease
- Pneumonia

Musculoskeletal diseases
- Spondylodiscitis
- Joint replacement follow-up

Other
- Giant cell arteritis
- Vasculitis
- Vascular prosthetic graft infection
- Inflammatory bowel disease
- Sarcoidosis
- Fever of unknown origin
- Inflammation of unknown origin

Background/Overview
POSITRON EMISSION TOMOGRAPHY
Positron emission tomography (PET) scans coupled positron-emitting radionuclide tracers to other molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as coincidence detection) by a PET scanner, which comprises multiple stationary detectors that encircle the region of interest.

A variety of tracers are used for PET scanning, including oxygen 15, nitrogen 13, carbon 11, and fluorine 18. The radiotracer most commonly used in oncology imaging has been fluorine 18, coupled with fluorodeoxyglucose (FDG), which has a metabolism related to glucose metabolism. While FDG has traditionally been used in cancer imaging, it potentially has many other applications.

EPILEPSY
Approximately one-third of patients with epilepsy do not achieve adequate seizure control with antiepileptic drugs. Individuals with drug-resistant epilepsy are candidates for other treatments such as surgery. Many effective surgical procedures are available and the treatment selected depends on characteristics of the seizures (eg, the epileptogenic zone) and the extent to which it can be resected safely. Neuroimaging techniques, such as magnetic resonance imaging (MRI), electroencephalography, PET, single-photon emission computed tomography (SPECT), electric and magnetic source imaging, and magnetic resonance...
spectroscopy, have been used to locate the epileptic focus, thereby helping to guide the operative strategy. Some patients with epilepsy will have no identifiable MRI abnormality to help identify the focal region. PET, particularly using FDG, is a neuroimaging technique frequently used in patients being considered for surgery. FDG-PET produces an image of the distribution of glucose uptake in the brain, presumably detecting focal areas of decreased metabolism. PET may be able to correctly identify the focus in patients with unclear or unremarkable MRI results or discordant MRI and electroencephalographic results that could reduce the need for invasive electroencephalography. PET scanning may also help to predict which patients will have a favorable outcome following surgery. The Engel classification system often used to describe the surgical outcome, is as follows: class I: seizure-free (or free of disabling seizures); class II: nearly seizure-free; class III: worthwhile improvement; and class IV: no worthwhile improvement.

**SUSPECTED CHRONIC OSTEOMYELITIS**
Foot infections can spread to contiguous deep tissues including the bone. Diagnosis of osteomyelitis is challenging. The reference standard for diagnosis is an examination of bacteria from a bone biopsy along with histologic findings of inflammation and osteonecrosis. In an open wound, another potential test for osteomyelitis is a probe-to-bone test, which involves exploring the wound for palpable bone using a sterile blunt metal probe. Plain radiographs are often used as screening tests before biopsy but they tend to have low specificity especially in early infection. When radiographs are inconclusive, a more sophisticated imaging technique can be used. Neither MRI nor computed tomography, both of which have high sensitivity in diagnosing osteomyelitis, can be used in patients with metal hardware. FDG-PET has high resolution that should be an advantage for accurate localization of leukocyte accumulation and can be used when MRI is not possible or inconclusive; in addition, PET semiquantitative analysis could facilitate the differentiation of osteomyelitis from noninfectious conditions such as neuropathic arthropathy.

**SUSPECTED ALZHEIMER DISEASE**
Definitive diagnosis of Alzheimer disease (AD) requires histopathologic examination of brain tissue obtained by biopsy or autopsy. In practice, clinical criteria based on clinical examination, neurologic and neuropsychological examinations, and interviews with informants (eg, family members or caregivers) are used to diagnose AD by excluding other diseases that can cause similar symptoms, and distinguish AD from other forms of dementia. There are currently no curative or preventive therapies for AD. Early diagnosis might facilitate early treatment of cognitive, behavioral, and psychiatric symptoms which could perhaps delay functional deficits and improve quality of life. Early diagnosis may be crucial in the future if other therapies become available to treat or slow progression of the disease. FDG-PET can demonstrate a reduction in glucose metabolism associated with dementia. These changes in metabolism are detectable years before the onset of clinical symptoms. The changes typically have a characteristic pattern of hypometabolism that could be useful not only in distinguishing AD from normal aging but also from other dementias, psychiatric disorders, and cerebrovascular diseases.
LARGE VESSEL VASCULITIS

Large vessel vasculitis causes granulomatous inflammation primarily of the aorta and its major branches. There are 2 major types of large vessel vasculitis: giant cell arteritis and Takayasu arteritis. Classification criteria for giant cell arteritis and Takayasu arteritis were developed by American College of Rheumatology in 1990. The definitions have since been refined by the International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (2012). Biopsy and angiography are considered the criterion standard techniques for diagnosis, but they are invasive and detect changes that occur late in the disease. In practice, the diagnosis is challenging because patients tend to have nonspecific symptoms such as fatigue, loss of appetite, weight loss, and low-grade fever as well as nonspecific lab findings such as increased C-reactive protein or erythrocyte sedimentation rate. Misdiagnosis is common particularly during the early stages of the disease. Unfortunately, late diagnosis can lead to serious aortic complications and death. Since activated inflammatory cells accumulate glucose, FDG-PET may be able to detect and visualize early inflammation in vessel walls and facilitate early diagnosis thereby allowing treatment with glucocorticoids before irreversible arterial damage has occurred.

This evidence review only addresses the use of radiotracers detected with the use of dedicated full-ring PET scanners. Radiotracers such as FDG may be detected using SPECT cameras, a hybrid PET/SPECT procedure that may be referred to as FDG-SPECT or molecular coincidence detection. The use of SPECT cameras for PET radiotracers presents unique issues of diagnostic performance and is not considered herein.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Following the U.S. FDA approval of the Penn-PET in 1989, a number of PET scan platforms have been cleared by FDA through the 510(k) process. These systems are intended to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and organ function for the evaluation of diseases, and disorders such as, but not limited to, cardiovascular disease, neurologic disorders, and cancer. The images produced by the system can aid in radiotherapy treatment planning and interventional radiology procedures.

PET radiopharmaceuticals have been evaluated and approved as drugs by FDA for use as diagnostic imaging agents. These radiopharmaceuticals are approved for specific conditions.

In December 2009, FDA issued guidance for Current Good Manufacturing Practice for PET drug manufacturers and, in August 2011, issued similar Current Good Manufacturing Practice guidance for small businesses compounding radiopharmaceuticals. An additional final guidance document, issued in December 2012, required all PET drug manufacturers and compounders to operate under an approved new drug application (NDA) or abbreviated NDA, or investigational new drug application, by December 12, 2015.

In 1994, the FDG radiotracer was originally approved by FDA through the NDA (20-306) process. The original indication was for “the identification of regions of abnormal glucose metabolism associated with foci of
epileptic seizures”. Added indications in 2000 were for “Assessment of glucose metabolism to assist in the evaluation of malignancy...” and “Assessment of patients with coronary artery disease and left ventricular dysfunction...”. (Note that many manufacturers have NDAs for FDG.)

Multiple manufacturers have approved NDAs for FDG.

Centers for Medicare and Medicaid Services (CMS)
In 2004, the CMS made public its final decision memorandum announcing a positive national coverage decision for a subset of patients “with a recent diagnosis of dementia and documented cognitive decline of at least 6 months, who meet diagnostic criteria for both [Alzheimer disease] and frontotemporal dementia, who have been evaluated for specific alternative neurodegenerative diseases or causative factors, and for whom the cause of the clinical symptoms remains uncertain.” For its reconsideration, CMS requested an updated Agency for Healthcare Research and Quality assessment, which concluded that no new publications provided direct evidence to evaluate the use of PET to either differentiate among different types of dementia or to identify those patients with mild cognitive impairment who were at greatest risk to progress to AD. Additionally, CMS considered a consensus report by the Neuroimaging Work Group of the Alzheimer’s Association and proceedings of an expert panel discussion of neuroimaging in AD, convened by the National Institute of Aging and Medicare.

The national coverage determination for FDG-PET for dementia and neurodegenerative diseases (220.6.13) states that:
“Medicare covers FDG PET scans for either the differential diagnosis of fronto-temporal dementia (FTD) and AD under specific requirements; OR, its use in a CMS-approved practical clinical trial focused on the utility of FDG PET in the diagnosis or treatment of dementing neurodegenerative diseases.”

Specific requirements for each indication are clarified in the document.

The national coverage determination for FDG-PET for infection and inflammation (220.6.16) states that:
“The CMS is continuing its national noncoverage of FDG PET for the requested indications. Based upon our review, CMS has determined that the evidence is inadequate to conclude that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin improves health outcomes in the Medicare populations, and therefore has determined that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin is not reasonable...”

Rationale/Source
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.
The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**FLUORINE 18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY**

**Clinical Context and Test Purpose**

The purpose of fluorine 18 fluorodeoxyglucose PET (FDG-PET) in patients with epilepsy, chronic osteomyelitis, suspected Alzheimer disease (AD), suspected large vessel vasculitis (LVV), or other noncardiac or nononcologic conditions is to confirm a diagnosis or to inform the decision on selecting treatment regimens.

The question addressed in this evidence review is: Does the use of FDG-PET improve the net health outcome in individuals with epilepsy, chronic osteomyelitis, suspected AD, suspected LVV, or other noncardiac or nononcologic conditions?

The following PICOTS were used to select literature to inform this review.

**Patients**
The populations of interest include patients with epilepsy, chronic osteomyelitis, suspected AD, suspected LVV, or other noncardiac or nononcologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases).

**Interventions**
The intervention of interest is FDG-PET.

**Comparators**
The following tests and practices are currently being used to make decisions about managing the following indications:

- For epilepsy, ictal scalp electroencephalography and magnetic resonance imaging (MRI).
- For suspected chronic osteomyelitis, computed tomography (CT), radiography, technetium 99 bone scintigraphy, leukocyte scintigraphy, and MRI.
- For suspected AD, clinical diagnosis without FDG-PET.
- For suspected LVV, clinical diagnosis without FDG-PET.
- For diverse noncardiac or nononcologic conditions, CT, radiograph, and MRI.

**Outcomes**
For patients with epilepsy, 2 outcomes of interest are: (1) to identify the epileptic focus accurately before surgery and (2) to predict which patients will have a favorable outcome following surgery.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

For patients with suspected AD, suspected chronic osteomyelitis, and suspected LVV, or other noncardiac or nononcologic conditions, outcomes of interest include disease-related morbidity and mortality.

**Timing**
For patients with epilepsy, FDG-PET would be conducted prior to surgery.

For patients with suspected AD, suspected chronic osteomyelitis, suspected LVV, or other noncardiac or nononcologic conditions, FDG-PET would be performed following inconclusive clinical examinations and standard radiographs.

**Setting**
FDG-PET is administered in an imaging center equipped with a PET scanner.

**Epilepsy**

**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Systematic Reviews**
A TEC Assessment (1996) reviewed the evidence on the use of PET in individuals with seizure disorders from 12 studies in which the results of PET scans were correlated with results of an appropriate reference standard test. The highest quality blinded study (N=143) reported that PET correctly localized the seizure focus in 60% of patients, incorrectly localized it in 6%, and was inconclusive in 34%. Reviewers concluded that because localization can be improved with PET, selection of surgical candidates is improved and, therefore, PET for assessing patients who have medically refractory complex partial seizures and are potential candidates for surgery met TEC criteria. All other uses of PET for the management of seizure disorders did not meet the TEC criteria. Tables 1 and 2 summarize the characteristics and results of several meta-analyses of FDG-PET published since that TEC Assessment that have assessed either presurgical planning of patients who are candidates for epilepsy surgery or prediction of surgical outcomes. A brief discussion of each trial follows.

**Table 1. Characteristics of Systematic Reviews Assessing Use of FDG-PET for Epilepsy**

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>N (Range)</th>
<th>Design</th>
<th>Outcomes</th>
</tr>
</thead>
</table>

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Jones et al (2016) published a systematic review of neuroimaging for surgical treatment of temporal lobe epilepsy. Inclusion criteria were systematic reviews, randomized controlled trials (RCTs), or observational studies (with >20 patients and at least 1-year follow-up) of neuroimaging in the surgical evaluation for temporal lobe epilepsy. Reviewers searched EMBASE, MEDLINE, and Cochrane databases. Twenty-seven studies with 3163 patients were included in the review, of which 11 observational studies with 1358 patients evaluated FDG-PET. Good surgical outcome was defined as Engel classes I and II. Meta-analysis was not performed. Results are summarized in Table 2.

Wang et al (2016) conducted a systematic review of prognostic factors for seizure outcomes in patients with MRI-negative temporal lobe epilepsy included a search of MEDLINE. Eighteen studies (total N=391 patients) were included with a mean or median follow-up of more than 1 year. Seizure freedom was defined as freedom from any type of seizure or an Engel class I seizure outcome. Odds ratios and corresponding 95% confidence intervals (CIs) were calculated to compare the pooled proportions of seizure freedom between the groups who had localization of hypometabolism in the resected lobe vs those who did not. Table 2 shows the summary results.

Burneo et al (2015) published a recommendation report for the Program in Evidence-based Care and the PET steering committee of Cancer Care Ontario, which was based on a systematic review of studies of diagnostic accuracy and clinical utility of FDG-PET in the presurgical evaluation of adult and pediatric patients with medically intractable epilepsy. The literature review included searches of the MEDLINE, EMBASE, OVID, and Cochrane databases. Systematic reviews, RCTs, and observational studies that evaluated the use of FDG-PET in medically intractable epilepsy were eligible for inclusion. Reviewers included 39 observational studies (total N=2650 participants) in the qualitative review. Good surgical outcome was defined as Engel class I, II, or III, seizure-free, or significant improvement (<10 seizures per year and at least a 90% reduction in seizures from the preoperative year). Due to heterogeneity in patient populations, study designs, outcome measurements, and methods of PET interpretation, pooled estimates were not provided; ranges are provided in Table 2.

Englot et al (2012) performed a systematic review of predictors of long-term seizure freedom after surgery for frontal lobe epilepsy; they included articles found through a MEDLINE search that had at least 10 participants and 48 months of follow-up. Long-term seizure freedom was defined as Engel class I outcome. Twenty-one studies (total N=1199 patients) were included; the number of studies that specifically addressed PET was not
Willmann et al (2007) conducted a meta-analysis on the use of FDG-PET for preoperative evaluation of adults with temporal lobe epilepsy included 46 studies published identified through a MEDLINE search. Follow-up ranged from 3 to 144 months. Engel class I and II were defined as a good surgical outcome. The prognostic positive predictive value (PPV) for ipsilateral PET hypometabolism was calculated, but the reviewers noted significant variation in study designs and lack of precise data. Reviewers found that ipsilateral PET hypometabolism had a predictive value for a good outcome of 86% (see Table 2). The incremental benefit of PET was unclear.

### Table 2. Results of Systematic Reviews on Use of FDG-PET for Epilepsy

<table>
<thead>
<tr>
<th>Study</th>
<th>Studies</th>
<th>N</th>
<th>Outcomes</th>
<th>Estimate or Range</th>
<th>95% CI</th>
<th>$f^2$</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones et al (2016)</td>
<td>11</td>
<td>1358</td>
<td>Surgical outcome</td>
<td>• No overall summary given</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Reported conflicting findings on prognostic importance of PET-identified focal hypometabolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang et al (2016)</td>
<td>5</td>
<td>NR</td>
<td>Surgical outcome (freedom from seizures)</td>
<td>OR for PET hypometabolism positive vs negative, 2.11</td>
<td>0.95 to 4.65</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Burneo et al (2015)</td>
<td>8</td>
<td>310</td>
<td>Percent agreement, localization with PET vs EEG</td>
<td>• 56%-90% overall (adults)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 63%-90% in temporal lobe epilepsy (adults)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>1064</td>
<td>Prognostic accuracy (good surgical outcome)</td>
<td>36%-89% (adults)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>690</td>
<td>Clinical decisions (influence decision making)</td>
<td>• 53%-71% (adults)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 51%-95% (children)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Englot et al (2012)</td>
<td>21a</td>
<td>1199a</td>
<td>Prognostic accuracy (good surgical outcome)</td>
<td>% for PET focal vs PET nonfocal, 52% vs 48%</td>
<td>NR</td>
<td>NR</td>
<td>0.61</td>
</tr>
<tr>
<td>Willmann et al (2007)</td>
<td>46</td>
<td>1112</td>
<td>Prognostic accuracy (good surgical outcome)</td>
<td>PPV=86%</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
Observational Studies
In a study published after the most recent systematic reviews, Traub-Weidinger et al (2016) reviewed a database of pediatric patients with epilepsy who underwent hemispherotomy and were evaluated with both FDG-PET and MRI before surgery (N=35). Identifying the hemisphere harboring the epileptogenic zone before surgery has been shown to improve surgical outcomes. Seizure outcomes were measured using International League Against Epilepsy classifications. At 12 months postsurgery, 100% of patients with unilateral FDG-PET hypometabolism were seizure-free, while 95% of patients with unilateral lesions identified by MRI were seizure-free. For patients with bilateral FDG-PET hypometabolism, 75% were seizure-free at 12 months, while 71% of patients with bilateral lesions identified by MRI were seizure-free.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

The recommendation report by Burneo et al (2015) discussed 3 retrospective studies demonstrating the impact of FDG-PET on clinical management of adults with epilepsy and 3 retrospective studies on change in clinical management based on FDG-PET results in children with epilepsy. After receiving FDG-PET results on adults, some clinicians changed surgical decisions, used the results to guide intracranial electroencephalography, and ruled out an additional evaluation of the patient. Among pediatric patients who underwent FDG-PET, clinicians reported using the results to alter surgical decisions, classify symptomatic infantile spasms, and avoid invasive monitoring due to localizing information. The study results were not pooled due to heterogeneity among the study designs and patient populations.

Section Summary: Epilepsy
The TEC Assessment and the Program in Evidence-based Care recommendations summarized evidence on the use of PET to localize seizure foci for presurgical evaluation. Although data were exclusively from observational studies and the results were heterogeneous, the findings generally supported the use of PET for presurgical evaluation of adult and pediatric patients with intractable epilepsy to localize foci. For predicting which patients would have a favorable surgery outcome, the data on PET were mixed but supported a possible moderate relation between PET findings and prognosis. There are several retrospective studies that surveyed clinicians on the utility of FDG-PET in managing patients with epilepsy. In general, the clinicians...
reported that the information from FDG-PET was helpful in surgical management decisions. Only observational studies are available, most having small samples sizes with varying patient characteristics and definitions of good surgical outcomes.

**Suspected Chronic Osteomyelitis**

*Technically Reliable*

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Systematic Reviews**

Lauri et al (2017) published a systematic review of 27 trials of diabetic patients with suspicion of osteomyelitis of the foot that compared the diagnostic performance of several imaging techniques. MRI, technetium 99m hexamethylpropyleneamineoxime white blood cell (WBC) scan, indium In 111 oxyquinoline WBC scan, or FDG-PET plus CT were assessed. In this population, the sensitivity and specificity of FDG-PET/CT (6 studies; 254 patients) were 89% (95% CI, 68% to 97%) and 92% (95% CI, 85% to 96%), respectively. The diagnostic odds ratio for FDG-PET was 95, and the positive and negative likelihood ratios were 11 and 0.11, respectively. Of the 4 modalities included, FDG-PET/CT and technetium 99m hexamethylpropyleneamineoxime WBC scans had greater specificity (both 92%) than MRI or In-oxine WBC scans (both 75%). Sensitivity did not differ significantly between modalities: 93% for MRI, 92% for indium In 111 oxyquinoline WBC, 91% for technetium 99m hexamethylpropyleneamineoxime WBC, and 89% for FDG-PET. The review was limited by the small size of studies included, which precluded subgroup or meta-regression analyses.

A systematic review by Treglis et al (2013) assessed 9 studies (total N=299 patients), FDG-PET and PET with CT were found to be useful for assessing suspected osteomyelitis in the foot of patients with diabetes. A meta-analysis of 4 studies found a sensitivity of 74% (95% CI, 60% to 85%), a specificity of 91% (95% CI, 85% to 96%), a positive likelihood ratio of 5.56 (95% CI, 2.02 to 15.27), a negative likelihood ratio of 0.37 (95% CI, 0.10 to 1.35), and a diagnostic odds ratio of 16.96 (95% CI, 2.06 to 139.66). The summary area under the receiver operating characteristic curve was 0.874.

Termaat et al (2005) conducted a systematic review of diagnostic imaging to assess chronic osteomyelitis. Reviewers assessed 6 imaging approaches to chronic osteomyelitis, including FDG-PET, and concluded that PET was the most accurate mode (pooled sensitivity, 96%; 95% CI, 88% to 99%; pooled specificity, 91%; 95% CI, 81% to 95%) for diagnosing chronic osteomyelitis, including leukocyte scintigraphy was adequate in the peripheral skeleton (sensitivity, 84%; 95% CI, 72% to 91%; specificity, 80%; 95% CI, 61% to 91%) but
was inferior in the axial skeleton (sensitivity, 21%; 95% CI, 11% to 38%; specificity, 60%; 95% CI, 39% to 78%). The assessment of PET was based on 4 prospective, European studies published between 1998 and 2003 (total N=1660 patients). However, the study populations varied and included the following: (1) 57 patients with suspected spinal infection referred for FDG-PET and who had previous spinal surgery but not “recently”; (2) 22 trauma patients scheduled for surgery who had suspected metallic implant–associated infection; (3) 51 patients with recurrent osteomyelitis or osteomyelitis symptoms for more than 6 weeks, 36 in the peripheral skeleton and 15 in the central skeleton; and (4) 30 consecutive nondiabetic patients referred for possible chronic osteomyelitis. The results appeared to be robust across fairly diverse clinical populations, which strengthen the conclusions.

Prospective Studies
Rastogi et al (2016) published a study comparing the efficacy of FDG-PET plus CT with contrast-enhanced MRI in the detection of diabetic foot osteomyelitis in patients with Charcot neuroarthropathy. Patients with suspected diabetic foot osteomyelitis (N=23) underwent radiographs, FDG-PET/CT, and contrast-enhanced MRI. Bone culture, which is considered the criterion standard, identified 12 of the 23 patients with osteomyelitis. The sensitivity, specificity, PPV, and negative predictive value (NPV) of FDG-PET/CT in diagnosing osteomyelitis were 83%, 100%, 100%, and 85%, respectively. The same measures for contrast-enhanced MRI were 83%, 64%, 71%, and 78%, respectively.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs identified assessed the evidence on the clinical utility of FDG-PET for diagnosing osteomyelitis.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Diagnosing osteomyelitis is challenging and FDG-PET may provide additional information along the diagnostic pathway. Currently, bone biopsy is considered the reference standard, and radiographs are often used as screening tests prior to bone biopsy. When radiographs are inconclusive, other imaging techniques have been used, such as MRI and CT. While MRI has been shown to have a high sensitivity in diagnosing...
osteomyelitis, FDG-PET has also been shown to have high sensitivity and can be used when MRI is inconclusive or not possible (eg, patients with metal hardware).

**Section Summary: Suspected Chronic Osteomyelitis**
Evidence for the use of FDG-PET to diagnose chronic osteomyelitis includes 3 systematic reviews and a prospective study published after the systematic reviews. FDG-PET and FDG-PET/CT were found to have high specificity and PPVs in diagnosing osteomyelitis. Compared with other modalities, FDG-PET and FDG-PET/CT were found to have better diagnostic capabilities than contrast-enhanced MRI and leukocyte scintigraphy.

**Suspected Alzheimer Disease**
This evidence review does not discuss PET tracers that bind to amyloid beta plaques.

**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Systematic Reviews**
Summaries of the characteristics and results of several meta-analyses of the early diagnosis of AD in people with cognitive impairment or for differentiating between potential causes of dementia are shown in Tables 3 and 4 and are briefly described below.

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Studies</th>
<th>N (Range)</th>
<th>Design</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smailagic et al</td>
<td>1999-2013</td>
<td>16</td>
<td>697 (19-94)</td>
<td>OBS</td>
<td>Diagnostic accuracy for predicting conversion from MCI to AD</td>
</tr>
<tr>
<td>Davison et al</td>
<td>Up to 2013</td>
<td>8</td>
<td>197 (7-199)</td>
<td>OBS</td>
<td>Diagnostic accuracy for diagnosis of AD, differential diagnosis in dementia, predicting conversion from MCI to AD</td>
</tr>
<tr>
<td>Bloudek et al</td>
<td>1990-2010</td>
<td>119</td>
<td>NR</td>
<td>OBS</td>
<td>Diagnostic accuracy for diagnosis of AD, differential diagnosis in dementia</td>
</tr>
<tr>
<td>Yuan et al</td>
<td>2001-2005</td>
<td>6</td>
<td>280 (17-128)</td>
<td>OBS</td>
<td>Diagnostic accuracy for predicting conversion from MCI to AD</td>
</tr>
</tbody>
</table>
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy #  00104
Original Effective Date:  01/28/2002
Current Effective Date:  03/09/2019


AD: Alzheimer disease; FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; MCI: mild cognitive impairment; NR: not reported; OBS: observational.

Smailagic et al (2015) conducted a Cochrane review to assess the diagnostic accuracy of FDG-PET for detecting people who clinically convert to AD or other forms of dementia at follow-up. Included studies evaluated the diagnostic accuracy of FDG-PET to determine the conversion from mild cognitive impairment (MCI) to AD or to other forms of dementia. Sixteen studies (total N=697 participants) were included in the qualitative review and 14 studies (n=421 participants) were included in the analysis. Because there are no accepted thresholds to define positive findings based on PET scans and studies used mixed thresholds for diagnosis, reviewers used a hierarchical summary receiver operating characteristic curve to derive pooled estimates of performance characteristics at fixed values. Results are shown in Table 4. Five studies evaluated the accuracy of FDG-PET for all types of dementia. The sensitivities ranged between 46% and 95% while the specificities between 29% and 100%; however, a meta-analysis could not be conducted because of the small number of studies sample sizes. Reviewers indicated that most studies were poorly reported and had an unclear risk of bias, mainly for the reference standard and participant selection domains.

In a systematic review (quality assessment of included studies was not reported), Davison et al (2014) reported on studies on the diagnostic performance of FDG-PET and single-photon emission computed tomography identified through MEDLINE. Three studies (197 patients) used histopathology as the reference standard. In patients with or without a clinical diagnosis of AD, sensitivity was 84% and specificity was 74%; in patients with memory loss or dementia, sensitivity was 94% and specificity was approximately 70%; in patients undergoing evaluation for dementia, sensitivity was 94% and specificity was 73%. Precision estimates were not given. In 3 different studies (271 participants), the sensitivities and specificities of FDG-PET for distinguishing AD from Lewy body dementia ranged from 83% to 99% and from 71% to 93%, respectively. And in 2 studies (183 participants), for predicting conversion from MCI to AD, sensitivity and specificity of PET ranged from 57% to 82% and from 67% to 78%, respectively.

Bloudek et al (2011) assessed diagnostic strategies for AD in a meta-analysis. Reviewers included 119 studies of diagnostic performance characteristics published from 1990 to 2010. Studies were identified through a search of MEDLINE and included imaging, biomarkers, and clinical diagnostic strategies. Twenty studies included performance characteristics of FDG-PET for diagnosing AD compared with normal, nondemented controls. Thirteen studies described characteristics of FDG-PET for diagnosing AD compared with demented controls. FDG-PET demonstrated the highest area under the receiver operating characteristic curve, sensitivity, and specificity among all of the diagnostic methods for distinguishing AD from normal controls but one of the lowest receiver operating characteristic comparing AD with non-AD demented controls (excluding MCI), due primarily to the low specificity in this group. Results are shown in Table 4.
In a meta-analysis, Yuan et al (2009) compared the prognostic capacity of FDG-PET, single-photon emission computed tomography, and structural MRI to predict patients’ conversion from MCI to AD. Using 24 articles (total N=1112 patients) published between 1990 to 2008 (6 studies with 280 patients on FDG-PET, published 2001-2005), reviewers found no statistically significant difference among the 3 modalities in pooled sensitivity, pooled specificity, or negative likelihood ratio. Results are shown in Table 4. There was strong evidence of between-study heterogeneity and marked asymmetry in the funnel plot (with studies missing from the bottom left quadrant), indicating possible publication bias of studies with null results. Efforts to identify sources of heterogeneity (eg, publication year, age, male-female ratio, follow-up interval, years of education, mean Mini-Mental State Examination score at baseline) yielded no significant results.

Using decision-analysis modeling, Matchar et al (2001) performed a technology assessment for the Agency for Healthcare Research and Quality to examine whether the use of FDG-PET would improve health outcomes for diagnosis of AD in 3 clinical populations: patients with dementia, patients with MCI, and subjects with no symptoms but with a first-degree relative with AD. For the review, a search was performed using MEDLINE, CINAHL, and the HealthSTAR databases. Eighteen articles (total N=1018 participants) were included. The reference standard used in the studies was either histopathology or clinical diagnosis. Studies reported on various cutoffs for PET positivity, and, therefore, an unweighted summary receiver operating characteristic method was used to calculate the pooled area under the curve. Results are summarized in Table 4. Reviewers concluded that outcomes for all 3 groups were better if all patients were treated with agents such as cholinesterase inhibitors rather than limiting treatment to patients based on FDG-PET results. The rationale was that the complications of treatment were relatively mild, and that treatment was considered to have some degree of efficacy in delaying the progression of AD.

<table>
<thead>
<tr>
<th>Study</th>
<th>Studies</th>
<th>N</th>
<th>Outcomes</th>
<th>Estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smailagic et al (2015)</td>
<td>14</td>
<td>421</td>
<td>Diagnostic accuracy</td>
<td>• Sensitivity range: 25%-100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Specificity range: 15%-100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• PLR: 4.03 (2.97 to 5.47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• NLR: 0.34 (0.15 to 0.75)</td>
</tr>
<tr>
<td>Davison et al (2014)</td>
<td>3</td>
<td>197</td>
<td>Diagnostic accuracy</td>
<td>• Sensitivity: 84%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Specificity: 74%</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>183</td>
<td>Diagnostic accuracy, predicting conversion</td>
<td>• Sensitivity range: 57%-82%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>from MCI to AD</td>
<td>• Specificity range: 67%-78%</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>292</td>
<td>Diagnostic accuracy, differentiating AD and</td>
<td>• Sensitivity range: 83%-92%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LBD</td>
<td>• Specificity range: 67%-93%</td>
</tr>
<tr>
<td>Bloudek et al (2011)</td>
<td>20</td>
<td>NR</td>
<td>Diagnostic accuracy</td>
<td>• Sensitivity: 90% (84% to 94%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Specificity: 89% (81% to 94%)</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>NR</td>
<td>Diagnostic accuracy, AD vs other dementia</td>
<td>• Sensitivity: 92% (84% to 96%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Specificity: 78% (69% to 85%)</td>
</tr>
</tbody>
</table>
### Study Outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Outcomes</th>
<th>Estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuan et al (2009)</td>
<td>280</td>
<td>Diagnostic accuracy</td>
<td>Sensitivity: 89% (92% to 94%) Specificity: 85% (78% to 90%) PLR: 4.6 (3.2 to 6.7) NLR: 0.15 (0.05 to 0.48)</td>
</tr>
<tr>
<td>Matchar et al (2001)</td>
<td>729</td>
<td>Diagnostic accuracy</td>
<td>Sensitivity: 88% (79% to 94%) Specificity: 87% (77% to 93%)</td>
</tr>
<tr>
<td></td>
<td>289</td>
<td>Diagnostic accuracy, distinguishing AD from non-AD dementia</td>
<td>Sensitivity range: 86% to 95% Specificity range: 61% to 74%</td>
</tr>
</tbody>
</table>

- **AD**: Alzheimer disease; **CI**: confidence interval; **FDG-PET**: fluorine 18 fluorodeoxyglucose positron emission tomography; **LBD**: Lewy body dementia; **MCI**: mild cognitive impairment; **NLR**: negative likelihood ratio; **NR**: not reported; **PLR**: positive likelihood ratio.

### Retrospective Studies

In a study published after the systematic reviews, Pagani et al (2017) tested the accuracy of FDG-PET to discriminate between patients with MCI who progressed to AD and those who did not progress. The study population consisted of 42 normal elderly patients without MCI, 27 patients with MCI who had not converted to AD after a follow-up of at least 5 years since the first FDG-PET scan (mean follow-up, 7.5 years), and 95 patients with MCI who converted to AD within 5 years of the baseline FDG-PET (mean time to conversion, 1.8 years). The group that progressed to AD within 5 years showed significantly lower FDG-PET uptake values in the temporoparietal cortex than the other groups. Baseline FDG-PET identified patients who converted to AD with an accuracy of 89%.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

Motara et al (2017) assessed the accuracy of dual-trained radiologists and nuclear medicine physicians to diagnose the type of cognitive impairment based on FDG-PET/CT images. Records of patients who had undergone FDG-PET/CT because of cognitive impairment (AD, frontotemporal dementia, mixed dementia, and dementia with Lewy bodies) following a negative CT or MRI scans were reviewed (N=136). Questionnaires were sent to the referring physicians to gather information on the final clinical diagnosis, usefulness of the PET/CT report, and whether the report impacted clinical management. The response rate was 72% (98/136) and mean patient follow-up was 471 days. For the diagnosis of AD, using the final clinical
diagnosis as the reference standard, the sensitivity, specificity, PPV, and NPV were 87%, 97%, 93%, and 91%, respectively. Questionnaires received from the 98 physicians indicated that PET/CT: was useful (78%); had an impact on clinical management (81%); added confidence to the pretest clinical diagnosis (43%); reduced the need for further investigations (42%); changed the pretest clinical diagnosis (35%); and led to a change in therapy (32%).

Section Summary: Suspected Alzheimer Disease
Several systematic reviews offer evidence on FDG-PET for diagnosing AD in people with cognitive impairment and for differentiating between AD and other dementias. Studies included in these reviews were generally poor quality. There is no standard cutoff for positive amyloid findings on PET scanning for diagnosing AD, and many studies did not include postmortem confirmation of AD as the reference standard. These limitations lead to uncertainty about estimates of performance characteristics. Although it appears that FDG-PET has high sensitivity and specificity, the evidence does not compare the performance characteristics of clinical diagnosis with PET to clinical diagnosis without PET, so the incremental value of adding PET to the standard clinical diagnosis is unclear. No studies reported on clinical outcomes of patients diagnosed with vs without FDG-PET. A single study was identified that surveyed physicians on the clinical utility of FDG-PET/CT in managing patients with cognitive impairment. In general, the physicians found the FDG-PET/CT helpful, but no clinical outcomes of patients were reported.

Suspected Large Vessel Vasculitis

Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Summaries of characteristics and results of several meta-analyses of FDG-PET that have been published on the diagnosis and management of LVV are shown in Tables 5 and 6 and are briefly described below.

Table 5. Characteristics of Systematic Reviews on Use of FDG-PET for Large Vessel Vasculitis

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Studies</th>
<th>N (Range)</th>
<th>Design</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al (2016)</td>
<td>Up to 2015</td>
<td>8</td>
<td>400 (21-93)</td>
<td>OBS</td>
<td>Diagnostic accuracy for GCA and TA</td>
</tr>
<tr>
<td>Soussan et al</td>
<td>2000-2013</td>
<td>21</td>
<td>712 (18-93)</td>
<td>OBS</td>
<td>Diagnostic accuracy for GCA; assessment of disease activity in TA</td>
</tr>
<tr>
<td>Puppo et al</td>
<td>1999-2014</td>
<td>19</td>
<td>977 (8-304)</td>
<td>OBS</td>
<td>Diagnostic accuracy for GCA</td>
</tr>
</tbody>
</table>

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Study Type</th>
<th>Disease Activity</th>
<th>Diagnostic Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treglia et al (2011)</td>
<td>Up to 2011</td>
<td>32</td>
<td>OBS</td>
<td>Diagnostic accuracy for GCA and TA; assessment of disease activity; monitor treatment response</td>
</tr>
<tr>
<td>Besson et al (2011)</td>
<td>Up to 2011</td>
<td>Unclear</td>
<td>OBS</td>
<td>Diagnostic accuracy for GCA</td>
</tr>
</tbody>
</table>

FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; GCA: giant cell arteritis; OBS: observational; TA: Takayasu arteritis.

Lee et al (2016) performed a meta-analysis of the diagnostic accuracy of FDG-PET and PET/CT for LVV. The search included studies indexed in PubMed, EMBASE, or Cochrane Library that used the American College of Rheumatology (ACR) classification system as the reference standard diagnosis. Eight studies (total N=400 participants) were identified for inclusion. Five studies included participants with both giant cell arteritis (GCA) and Takayasu arteritis (TA) while 3 included only GCA. Five studies evaluated FDG-PET and 3 evaluated FDG-PET/CT. Pooled estimates of sensitivity, specificity, positive likelihood ratio and negative likelihood ratio were calculated using a random-effects model and are shown in Table 6. Interpretation of these results was limited by the use of ACR as the reference standard and the varying levels of disease activity in selected studies.

Soussan et al (2015) conducted a literature review assessing the role of FDG-PET in the management of LVV, focused on 3 issues: determining the FDG-PET criteria for diagnosing vascular inflammation; establishing the performance of FDG-PET for the diagnosis of large vessel inflammation in GCA patients; and defining the performance of FDG-PET to evaluate the disease inflammatory activity in patients with TA. The MEDLINE, Cochrane Library, and EMBASE databases were searched for articles that evaluated the value of FDG-PET in LVV. Selection criteria included the use of the ACR classification for GCA or TA, the definition of a positive amyloid threshold for PET, and more than 4 cases included. The sensitivity and specificity of FDG-PET for the diagnosis of large vessel inflammation were calculated from each selected study and then pooled for meta-analysis with a random-effects model. Disease activity was assessed with the National Institutes of Health Stroke Scale or another activity assessment scale. Twenty-one studies (413 patients, 299 controls) were included in the systematic review. FDG-PET showed FDG vascular uptake in 70% (288/413) of patients and 7% (22/299) of controls. Only vascular uptake equal to or greater than the liver uptake differed significantly between GCA plus TA patients and controls (p<0.001). A summary of the results is shown in Table 6. FDG-PET showed good performances in the diagnosis of large vessel inflammation, with higher accuracy for diagnosing GCA patients than for detecting activity in TA patients. Although a vascular uptake equal to or greater than the liver uptake appears to be a good criterion for diagnosing vascular inflammation, further studies would be needed to define the threshold of significance as well as the clinical significance of the vascular uptake.

A systematic review by Puppo et al (2014) included studies of FDG-PET in GCA comparing the diagnostic performance of qualitative and semiquantitative methods of FDG-PET interpretation. Reviewers selected 19 studies (442 cases, 535 controls) found in PubMed or Cochrane Library. The selected studies had various reference standards. Ten used qualitative FDG uptake criteria to characterize inflammation, 6 used semiquantitative criteria, and 3 used both. Meta-analyses were not performed. Overall, qualitative methods...
were more specific but less sensitive, than semiquantitative methods. Diagnostic performance varied by vessel and by thresholds (cutoffs) for positivity. Results are shown in Table 6.

Treglia et al (2011) published a systematic review of PET and PET/CT in patients with LVV. Reviewers searched MEDLINE and Scopus for publications on the role of FDG-PET in LVV. Reviewers identified 32 studies (total N=604 vasculitis patients). Selected publications related to diagnosis, assessment of disease activity, the extent of disease, response to therapy, and prediction of relapse or complications. Reviewers did not pool findings. They concluded that: (1) PET and PET/CT may be useful for initial diagnosis and assessment of severity of disease; (2) appeared to be superior to MRI in the diagnosis of LVV, but not in assessing disease activity under immunosuppressive treatment, in predicting relapse, or in evaluating vascular complications; (3) the role of these imaging methods in monitoring treatment response is unclear. Reviewers also concluded that “given the heterogeneity between studies with regard to PET analysis and diagnostic criteria, a standardization of the technique is needed.” The studies cited in support of using PET for diagnosing LVV had small sample sizes.

Besson et al (2011) published a systematic review to assess use of FDG-PET for patients with suspected GCA; reviewers searched the MEDLINE, EMBASE, and the Cochrane databases. Studies were included if they evaluated the performance of FDG-PET for the diagnosis of GCA, had at least 8 participants, used ACR criteria as the reference standard to confirm diagnosis of GCA, and included a control group. Fourteen studies were identified; the number of participants in those studies was unclear. Six studies with 283 participants (101 vasculitis, 182 controls) were included in a meta-analysis. The meta-analysis calculated pooled estimates of sensitivity, specificity, PPV, NPV, positive and negative likelihood ratio, and diagnostic accuracy using a random-effects model. Results are shown in Table 6. There was statistically significant between-study heterogeneity for sensitivity, PPV, and NPV. All studies in the meta-analysis were small case-control studies.

### Table 6. Results of Systematic Reviews Assessing Use of FDG-PET for LVV

<table>
<thead>
<tr>
<th>Study</th>
<th>Studies</th>
<th>N</th>
<th>Outcomes</th>
<th>Estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al</td>
<td>8</td>
<td>400</td>
<td>Diagnostic accuracy of PET and PET/CT for GGA and TA</td>
<td>Sensitivity: 76% (68% to 82%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Specificity: 93% (89% to 96%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PLR: 7.27 (3.71 to 14.24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NLR: 0.30 (0.23 to 0.40)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>133</td>
<td>Diagnostic accuracy of PET and PET/CT for GCA</td>
<td>Sensitivity: 83% (72% to 91%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Specificity: 90% (80% to 96%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PLR: 7.11 (2.91 to 17.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NLR: 0.20 (0.11 to 0.34)</td>
</tr>
<tr>
<td>Soussan et al</td>
<td>4</td>
<td>233</td>
<td>Diagnostic accuracy for GCA</td>
<td>Sensitivity: 89.5% (78.5% to 96.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Specificity: 97.7% (94% to 99%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PLR: 28.7 (11.5 to 71.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NLR: 0.15 (0.07 to 0.29)</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>237</td>
<td>Diagnostic accuracy for disease activity in TA</td>
<td>Sensitivity: 87% (78% to 93%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Specificity: 73% (63% to 81%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PLR: 4.2 (1.5 to 12)</td>
</tr>
</tbody>
</table>
## Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

**Policy #** 00104  
**Original Effective Date:** 01/28/2002  
**Current Effective Date:** 03/09/2019

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

### Studies

#### NLR: 0.2 (0.1 to 0.5)

- **Sensitivity range:** 56%-77%
- **Specificity range:** 77%-100%
- **PPV range:** 93%-100%
- **NPV range:** 70%-82%

#### Sensitivity range: 56%-77%

- **Specificity range:** 77%-100%
- **PPV range:** 93%-100%
- **NPV range:** 70%-82%

#### Sensitivity range: 58%-90%

- **Specificity range:** 42%-95%
- **PPV range:** 79%-89%
- **NPV range:** 95%-98%

#### Sensitivity range: 65%-100%

- **Specificity range:** 45%-100%

#### No pooling; concluded that FDG-PET is useful “in the initial diagnosis and in the assessment of activity and extent of disease in patients with LVV”

#### Sensitivity: 80% (63% to 91%)

- **Specificity:** 89% (78% to 94%)
- **PPV:** 85% (62% to 95%)
- **NPV:** 88% (72% to 95%)
- **PLR:** 6.73 (3.55 to 12.77)
- **NLR:** 0.25 (0.13 to 0.46)

---

**CI:** confidence interval; **CT:** computed tomography; **FDG:** fluorine 18 fluorodeoxyglucose; **GCA:** giant cell arteritis; **LVV:** large vessel vasculitis; **NLR:** negative likelihood ratio; **NPV:** negative predictive value; **PET:** positron emission tomography; **PLR:** positive likelihood ratio; **PPV:** positive predictive value; **TA:** Takayasu arteritis.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs identified assessed the evidence on the clinical utility of FDG-PET for diagnosing LVV.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of FDG-PET for diagnosing LVV has not been established, a chain of evidence supporting its clinical utility cannot be constructed.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

Section Summary: Suspected Large Vessel Vasculitis
Several systematic reviews have evaluated the diagnosis and management of GCA using FDG-PET. Most studies included were small, many lacked controls, and all results were heterogeneous. Studies comparing PET with the true reference standard (biopsy or angiography) are rare. There are no consensus criteria to define the presence of vascular inflammation by FDG-PET in LVV, and different parameters with visual and semiquantitative methods have been reported. Studies demonstrating changes in management based on PET results or improvements in clinical outcomes are lacking.

Diverse Noncardiac or Nononcologic Conditions
Numerous systematic reviews have described the use of PET in patients with carotid stenosis; inflammatory diseases; fever of unknown origin; hyperinsulinemic hypoglycemia; spinal infections; mycobacterium infection; Creutzfeldt-Jakob disease; vascular prosthetic graft infection; prosthetic infection after knee or hip arthroplasty; inflammatory bowel disease; atypical parkinsonism; and Huntington disease. Many studies cited in these reviews were small, retrospective, and lacked standard definitions of PET interpretation and positivity; many did not directly compare one modality with another in the same patient group or correlate the PET results in individual patients to improved clinical outcomes.

A systematic review by Treglia et al (2011) addressed the use of FDG-PET in evaluating disease activity in patients with sarcoidosis. It did not include a quality assessment of individual studies. Only 3 small studies of 9 reviewed included data from a comparator imaging modality; thus, conclusions about comparative diagnostic performance cannot be reached.

In a systematic review of FDG-PET to diagnose prosthetic joint infection following hip or knee replacement, Kwee et al (2008) reported on a pooled sensitivity and specificity of 82.1% (95% CI, 68.0% to 90.8%) and 86.6% (95% CI, 79.7% to 91.4%), respectively. Reviewers noted significant heterogeneity among the 11 studies analyzed. Differences in performance were based on the location of prostheses (hip vs knee) and whether filtered back projection or iterative reconstruction was used. This meta-analysis and a study by Reinartz (2009) on the same clinical issue found that the specificity of PET was significantly greater for hip prostheses than for knee prostheses. Both author groups also noted that these results were based on the use of PET alone. CT is generally not useful in evaluating potential infections around joint prostheses because of the artifacts caused by the metallic implants, so additional research would be needed on combined PET/CT. The 2009 study compared the accuracy of PET with a triple-phase scan and with WBC imaging.

Section Summary: Diverse Noncardiac and Nononcologic Conditions
Systematic reviews have assessed the use of FDG-PET or FDG-PET/CT for diagnosing or managing carotid stenosis, various inflammatory and immune-mediated diseases, fever of unknown origin, and various infections. However, studies included in these reviews are mostly small, retrospective, and lack standard definitions of PET interpretation and positive findings. Few studies have compared PET with other diagnostic modalities and no studies have reported on patient clinical outcomes.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 23 of 31
SUMMARY OF EVIDENCE
For individuals who have epileptic seizures who are candidates for surgery who have FDG-PET, the evidence includes systematic reviews (following the publication of 3 TEC Assessments). Relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of life, hospitalizations, medication use, and resource utilization. The TEC Assessments and Program in Evidence-based Care PET recommendation report all concluded that FDG-PET accurately localizes the seizure focus compared with appropriate reference standards. A recent systematic review suggested it was difficult to discern the incremental value of FDG-PET in patients who have foci well localized by ictal scalp electroencephalography and magnetic resonance imaging. The evidence on whether FDG-PET has a predictive value for a good surgical outcome is mixed. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have suspected chronic osteomyelitis who receive FDG-PET, the evidence includes meta-analyses and a prospective study published after the meta-analyses. Relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, functional outcomes, quality of life, and hospitalizations. One systematic review and meta-analysis from 2013 of 9 studies revealed that FDG-PET and FDG-PET plus computed tomography were useful for diagnosing suspected osteomyelitis in the foot of patients with diabetes. The results of another meta-analysis (2005) showed that FDG-PET was the most accurate mode (pooled sensitivity, 96%; pooled specificity, 91%) for diagnosing chronic osteomyelitis. The results appear to be robust across fairly diverse clinical populations, which strengthen the conclusions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have suspected Alzheimer disease who receive FDG-PET, the evidence includes 5 systematic reviews of observational studies and a retrospective study assessing clinical utility. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, quality of life, and hospitalizations. The studies included in the reviews were generally of poor quality. There is no standard cutoff for PET positivity for diagnosing Alzheimer disease, and many studies have not included postmortem confirmation of Alzheimer disease as the reference standard, leading to uncertainty about estimates of performance characteristics. FDG-PET may have high sensitivity and specificity for diagnosing Alzheimer disease, but there is little evidence comparing the performance characteristics of clinical diagnosis using PET with the clinical diagnosis not using PET; therefore, the incremental value of adding PET to the standard clinical diagnosis is unclear. No studies have reported on clinical outcomes of patients diagnosed with and without FDG-PET. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have suspected large vessel vasculitis who receive FDG-PET, the evidence includes 5 systematic reviews of observational studies. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, morbid events, quality of life, hospitalizations, and treatment-related morbidity. Most studies included in the reviews were small and lacked controls. The reported performance characteristics were heterogeneous, but reviewers were unable to determine the source of heterogeneity.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy #: 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

Studies comparing PET with the true reference standard of biopsy or angiography are rare. There are no consensus criteria to define the presence of vascular inflammation by FDG-PET in large vessel vasculitis, and different parameters with visual and semiquantitative methods have been reported. Studies demonstrating changes in management based on PET results or improvements in clinical outcomes are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have diverse noncardiac or nononcologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases) who receive FDG-PET, the evidence includes a few systematic reviews. Relevant outcomes are overall survival, symptoms, change in disease status, functional outcomes, health status measures, quality of life, hospitalizations, medication use, and resource utilization. Many studies cited in the reviews were small, retrospective, and published in the 1990s to early 2000s; further, many studies did not directly compare a modality with another in the same patient group—nor did they correlate PET results in individual patients with improved clinical outcomes. Additional studies are needed to demonstrate FDG-PET results can change management, and therefore improve patient outcomes to support the utility of FDG-PET. The evidence is insufficient to determine the effect of the technology on health outcomes.

References
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019


©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.


Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019


©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy #  00104
Original Effective Date:  01/28/2002
Current Effective Date:  03/09/2019


Policy History
Original Effective Date:  01/28/2002
Current Effective Date:  03/09/2019
12/06/2001  Medical Policy Committee review
01/28/2002  Medical Policy Committee review. Format revision. No substance change to policy.
06/24/2002  Managed Care Advisory Council approval
07/06/2004  Medical Director review
07/20/2004  Medical Policy Committee review. Format revision. No substance change to policy.
07/26/2004  Managed Care Advisory Council approval
07/13/2005  Medical Director review
07/19/2005  Medical Policy Committee review
08/24/2005  Managed Care Advisory Council approval
07/07/2006  Format revision including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
09/06/2006  Medical Director review
09/20/2006  Medical Policy Committee approval. No changes to policy guidelines.
06/13/2007  Medical Director review
06/20/2007  Medical Policy Committee approval. Policy updated with literature search. Chronic osteomyelitis added as “may be considered medically necessary” and giant cell arteritis added as “investigational”.
07/02/2008  Medical Director review
07/16/2008  Medical Policy Committee approval. No change to coverage eligibility.
07/02/2009  Medical Director review
07/22/2009  Medical Policy Committee approval. No change to coverage eligibility.
01/01/2010  Coding Revision

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

07/01/2010 Medical Policy Committee approval
07/21/2010 Medical Policy Implementation Committee approval. Two additional dementia subtypes added to the investigational policy statement indications (frontotemporal dementia and dementia with Lewy Bodies).
07/07/2011 Medical Policy Committee approval
07/20/2011 Medical Policy Implementation Committee approval. Minor changes to policy statements (investigational indication for schizophrenia moved from dementias to psychiatric diseases and disorders; “vasculitis” added to investigational “other” category).
02/15/2012 Coding updated.
06/28/2012 Medical Policy Committee review
07/27/2012 Medical Policy Implementation Committee approval. Added (Non-cardiac, Non-oncologic)” to the policy title. Mycobacterium infection and inflammatory bowel disease added as investigational indications.
08/01/2013 Medical Policy Committee review
08/21/2013 Medical Policy Implementation Committee approval. Sarcoidosis added as an investigational indication.
08/07/2014 Medical Policy Committee review
08/20/2014 Medical Policy Implementation Committee approval. No change to coverage.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015 Medical Policy Committee review
11/16/2015 Medical Policy Implementation Committee approval. Vascular prosthetic graft infection, fever of unknown origin, and inflammation of unknown origin added as investigational indications. Assessment of cerebral blood flow in newborns revised but no other changes to policy statements.
12/01/2016 Medical Policy Committee review
12/21/2016 Medical Policy Implementation Committee approval. Title change, added “FDG” to investigational statement. Updated background, rationale and references.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017 Medical Policy Committee review
12/20/2017 Medical Policy Implementation Committee approval. Title changed
12/06/2018 Medical Policy Committee review
12/19/2018 Medical Policy Implementation Committee approval. No change to coverage.

Next Scheduled Review Date: 12/2019

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is
Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Policy # 00104
Original Effective Date: 01/28/2002
Current Effective Date: 03/09/2019

not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>78608, 78609, 78811, 78812, 78813, 78814, 78815, 78816</td>
</tr>
<tr>
<td>HCPCS</td>
<td>A9515, A9526, A9552, A9580, G0235</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:*

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association TEC or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:*

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.